What is the price-to-earnings ratio of Immuron?
The price-earnings ratio of Immuron is currently 9.59.
Immuron P/S 2024
Immuron P/S
9.59
Ticker
IMC.AX
ISIN
AU000000IMC7
WKN
A0RDPK
As of Sep 12, 2024, Immuron's P/S ratio stood at 9.59, a -69.29% change from the 31.23 P/S ratio recorded in the previous year.
The Immuron P/S history
Immuron Aktienanalyse
What does Immuron do?
Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Immuron's P/S Ratio
Immuron's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Immuron's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Immuron's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Immuron’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Immuron stock
How has the price-earnings ratio of Immuron changed compared to last year?
The price-to-earnings ratio of Immuron has increased by -69.29% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Immuron high compared to other companies?
Yes, the price-to-earnings ratio of Immuron is high compared to other companies.
How does an increase in the price-earnings ratio of Immuron affect the company?
An increase in the price-earnings ratio of Immuron would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Immuron affect the company?
A decrease in the price-earnings ratio of Immuron would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Immuron?
Some factors that influence the price-earnings ratio of Immuron are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Immuron pay?
Over the past 12 months, Immuron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immuron is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immuron?
The current dividend yield of Immuron is .
When does Immuron pay dividends?
Immuron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immuron?
Immuron paid dividends every year for the past 0 years.
What is the dividend of Immuron?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immuron located?
Immuron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immuron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immuron from 9/12/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Immuron pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Immuron in the year 2023?
In the year 2023, Immuron distributed 0 AUD as dividends.
In which currency does Immuron pay out the dividend?
The dividends of Immuron are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immuron
Our stock analysis for Immuron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
